Private company

Lucira Health, Inc.

American in vitro and in vivo diagnostic substances company1

In its 2022 annual report the company says: “We are a medical technology company on a mission to bring central laboratory quality testing for infectious diseases into the home and point of care settings. Our test kits are coupled with our digital platform, LUCI PASS, which is designed to securely deliver a clinically relevant test result to users, healthcare providers, and to required public health authorities.”44 It is headquartered in Emeryville, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryIn Vitro & In Vivo Diagnostic Substances1
  • HeadquartersEmeryville, California1
  • Incorporated inDE2
  • Business address1315 63Rd Street, Emeryville, Ca 946082
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

11.0%Gross margin3
-70.0%Operating margin3
-69.7%Net margin3
34492.9%Revenue growth, 20213
-34.3%Return on equity3
-$116.3MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue52¢$81.4M
  • Research and development25¢$39.8M
  • Selling, general and admin23¢$35.5M
  • Interest0¢$3.0K
  • Income tax0¢$17.0K

Out of $93.1M in revenue.3 The company lost money this year.

Financial statements

Revenue3$93.1M in 2021+34493% since 2020
0$25.0M$50.0M$75.0M$100.0M2020: $269.0K$269.0K20202021: $93.1M$93.1M2021+34493%
Gross profit3$10.2M in 2021
-$5.0M0$5.0M$10.0M$15.0M2020: -$1.7M-$1.7M20202021: $10.2M$10.2M2021
Operating income3-$65.1M in 2021+104% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$31.9M-$31.9M20202021: -$65.1M-$65.1M2021+104%
Net income3-$64.8M in 2021+74% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$37.3M-$37.3M20202021: -$64.8M-$64.8M2021+74%
Fiscal year201920202021
Revenue$269.0K3$93.1M3
Cost of revenue$1.9M3$81.4M3
Gross profit-$1.7M3$10.2M3
Research and development$24.6M3$39.8M3
Selling, general and admin$5.6M3$35.5M3
Operating expenses$75.4M3
Operating income-$31.9M3-$65.1M3
Interest$46.0K3$3.0K3
Income before tax-$64.8M3
Income tax$17.0K3
Net income-$37.3M3-$64.8M3

Compare Lucira Health, Inc. with another company

Corporate structure

Lucira Health, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Lucira Health, Inc.

  • EPIQ Capital Group, LLC Filed SC 13D/A on Lucira Health, Inc., latest Dec 22, 2022
  • Eclipse GP III, LLC Filed SC 13G on Lucira Health, Inc., latest Feb 14, 2022
  • Lucira Health, Inc. Emeryville, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Lucira Health, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$35.8M3 Dec 31, 2021$20.6M3 Dec 31, 2020+74.0%
Accumulated depreciation$4.8M3 Dec 31, 2021$1.2M3 Dec 31, 2020+314.1%
Property and equipment, net$31.0M3 Dec 31, 2021$19.4M3 Dec 31, 2020+59.6%
Operating-lease assets (leased space)$2.7M3 Dec 31, 2021$748.0K3 Dec 31, 2020+262.8%

Inventory

ItemLatestA year beforeChange
Inventory, total$50.8M3 Dec 31, 2021$4.9M3 Dec 31, 2020+943.7%
Work in process$10.5M3 Dec 31, 2021$140.0K3 Dec 31, 2020+7427.9%
Finished goods$4.3M3 Dec 31, 2021

Leadership

Who has led Lucira Health, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Erik T. Engelson2021–2023

President

  1. Erik T. Engelson2021–2023

Chief financial officer

  1. Dan George2021–2022
  2. Richard Clavano Narido2022–2023

Chief operating officer

  1. Hansgregory C. Hartmann2021
2025
Board members and other officers (15)

Timeline

  1. Sep 25, 20238-K Bankruptcy or receivership; Change to shareholders' rights; Executive or director change23
  2. Jun 12, 20238-K Other events24
  3. Apr 24, 20238-K Entered a material agreement; Completed an acquisition or sale; Other events25
  4. Apr 18, 20238-K Entered a material agreement26
  5. Apr 10, 20238-K Other events27
  6. Apr 5, 20238-K Other events28
  7. Feb 27, 20238-K Listing notice or transfer; Regulation FD disclosure29
  8. Feb 22, 20238-K Bankruptcy or receivership; Executive or director change; Regulation FD disclosure30
  9. Feb 21, 20238-K Executive or director change; Other events31
  10. Jan 13, 20238-K Executive or director change32
  11. Dec 28, 20228-K Ended a material agreement33
  12. Dec 19, 20228-K Listing notice or transfer34
  13. Feb 4, 2021New chief executive Erik T. Engelson becomes CEO6

Calendar

When it reported results

  1. Nov 14, 2022Reported quarterly or annual results35
  2. Aug 15, 2022Reported quarterly or annual results36
  3. May 12, 2022Reported quarterly or annual results37
  4. Mar 10, 2022Reported quarterly or annual results38
  5. Feb 8, 2022Reported quarterly or annual results39
  6. Jan 10, 2022Reported quarterly or annual results40
  7. Nov 12, 2021Reported quarterly or annual results41

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

86 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 30 major events, 40 insider forms, 2 large holders, 9 other. The latest 20:

  1. Oct 4, 202315-12G EDGAR
  2. Sep 25, 20238-K EDGAR
  3. Aug 15, 2023NT 10-Q EDGAR
  4. Jun 29, 2023S-8 POS EDGAR
  5. Jun 29, 2023S-8 POS EDGAR
  6. Jun 12, 20238-K EDGAR
  7. May 16, 2023NT 10-Q EDGAR
  8. Apr 24, 20238-K EDGAR
  9. Apr 18, 20238-K EDGAR
  10. Apr 13, 2023NT 10-K EDGAR
  11. Apr 10, 20238-K EDGAR
  12. Apr 5, 20238-K EDGAR
  13. Mar 13, 20234 FORM 4 SUBMISSION EDGAR
  14. Mar 13, 20234 FORM 4 SUBMISSION EDGAR
  15. Mar 13, 20234 FORM 4 SUBMISSION EDGAR
  16. Mar 13, 20234 FORM 4 SUBMISSION EDGAR
  17. Feb 27, 20238-K EDGAR
  18. Feb 22, 20238-K EDGAR
  19. Feb 21, 20234 FORM 4 SUBMISSION EDGAR
  20. Feb 21, 20238-K EDGAR

The 86 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

33 open-market trades by officers, directors and large owners since October 2021: 3 buys and 30 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 7, 2023Narido Richard ClavanoChief Financial OfficerSale2,382$0.45$1.1KForm 4
Mar 7, 2023Collins Kevin WalterChief Revenue OfficerSale81,717$0.48$39.2KForm 4
Mar 6, 2023Narido Richard ClavanoChief Financial OfficerSale1,910$0.57$1.1KForm 4
Mar 3, 2023Engelson Erik T.President and Chief ExecutiveSale634,666$1.04$657.3KForm 4
Mar 3, 2023Narido Richard ClavanoChief Financial OfficerSale25,091$1.09$27.3KForm 4
Mar 3, 2023Collins Kevin WalterChief Revenue OfficerSale30,102$1.15$34.6KForm 4
Mar 3, 2023Allen Anthony JosephChief Operations OfficerSale8,405$1.00$8.4KForm 4
Feb 16, 2023Kashmolah GhaziEx VP & Chief Quality OfficerSale5,028$0.27$1.4KForm 4
Dec 20, 2022Allen Anthony JosephChief Operations OfficerSale4,263$0.16$682Form 4
Dec 1, 2022Narido Richard ClavanoChief Financial OfficerSale1,583$0.36$570Form 4
Nov 28, 2022Kashmolah GhaziEx VP & Chief Quality OfficerSale7,537$0.42$3.2KForm 4
Nov 27, 2022Collins Kevin WalterChief Revenue OfficerSale9,666$0.42$4.1KForm 4
Nov 21, 2022Allen Anthony JosephChief Operations OfficerSale34,429$0.33$11.4KForm 4
Nov 17, 2022Kashmolah GhaziEx VP & Chief Quality OfficerSale33,247$0.37$12.4KForm 4
Nov 16, 2022Kashmolah GhaziEx VP & Chief Quality OfficerSale4,790$0.35$1.7KForm 4
Sep 20, 2022Allen Anthony JosephChief Operations OfficerSale17,052$1.39$23.7KForm 4
Sep 18, 2022George DanCFO and TreasurerSale343$1.38$473Form 4
Sep 15, 2022Engelson Erik T.President and Chief ExecutiveBuy20,000$1.82$36.4KForm 4
Sep 1, 2022Mitra DebkishoreChief Technology OfficerSale191$1.69$323Form 4
Aug 27, 2022Collins Kevin WalterChief Revenue OfficerSale8,580$1.72$14.8KForm 4

All 33 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Lucira Health, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLucira Health, Inc.1
  • CIK0001652724
  • Employer ID (EIN)27-24910371
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
  • Business address1315 63Rd Street, Emeryville, CA 946081
  • Phone(814) 574-15461
  • Shares outstanding40,598,954 as of Nov 7, 20225
  • Public float$192.9M as of Jun 30, 20213
  • On EDGAR sinceAug 7, 20191
  • Filings160 in all: 4 (57), 8-K (40), 3 (19), 10-Q (6), CORRESP (4), 10-K (2), NT 10-Q (2), S-8 (2)1
    All 33 form types

    S-8 POS (2), SEC STAFF LETTER (2), UPLOAD (2), 15-12G (1), 25-NSE (1), 3/A (1), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), D (1), D/A (1), DEF 14A (1), DEFA14A (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), NT 10-K (1), S-1 (1), S-1/A (1), S-1MEF (1), SC 13D (1), SC 13D/A (1), SC 13G (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2022
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) Apr 20, 2022
    Latest 8-K (8-K) Sep 25, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44